What is Zynerba Pharmaceuticals Financial Strength?
Zynerba Pharmaceuticals has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Zynerba Pharmaceuticals has no long-term debt (1).
As of today, Zynerba Pharmaceuticals's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Zynerba Pharmaceuticals's Financial Strength
For the Drug Manufacturers - Specialty & Generic subindustry, Zynerba Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zynerba Pharmaceuticals's Financial Strength Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zynerba Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Zynerba Pharmaceuticals's Financial Strength falls into.
Zynerba Pharmaceuticals Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Zynerba Pharmaceuticals's Interest Expense for the
months ended in Jun. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Jun. 2023 was $-11.14 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil.
Zynerba Pharmaceuticals's Interest Coverage for the quarter that ended in Jun. 2023 is
| Zynerba Pharmaceuticals had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Zynerba Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Zynerba Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Jun. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Zynerba Pharmaceuticals has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
80 West Lancaster Avenue, Suite 300, Devon, PA, USA, 19333
Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Executives
| Kenneth T Jones |
officer: See Remarks |
C/O ZYNERBA PHARMACEUITCALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
| Brian Rosenberger |
officer: VP, Commercial & Business Dev. |
C/O ZYNERBA PHARMACEUTICALS, INC., 80 WEST LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
| Terri B Sebree |
officer: President |
ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
| James E Fickenscher |
officer: Chief Financial Officer |
C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19087 |
| Armando Anido |
director, officer: Chairman & Chief Exec. Officer |
80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
| Kenneth I Moch |
director |
68 WILLOW AVE, LARCHMONT NY 10538 |
| Warren D Cooper |
director |
NUTRITION 21 INC, 4 MANHATTANVILLE ROAD, PURCHASE NY 10577 |
| Pamela Stephenson |
director |
C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
| John P. Butler |
director |
C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063 |
| Daniel L Kisner |
director |
2292 FARADAY AVENUE, CARLSBAD CA 92008 |
| William J Federici |
director |
530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
| Albert P Parker |
officer: Chief Legal Officer |
C/O ONCOCYTE CORPORATION, 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
| Suzanne M. Hanlon |
officer: Sec, General Counsel & VP HR |
80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
| Michael Rapp |
10 percent owner |
712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019 |
| Thomas L Harrison |
director |
|
Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZYNE has been successfully added to your